Background: Previously, we identified the highly immunogenic cancer testicular antigen named Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1). In this study, we analyzed the effect of KK-LC-1 expression on the prognosis of patients with resected squamous cell lung cancer.
Methods: Fifty squamous cell lung cancer patients, who received complete resection, were enrolled in this study. The expressions of KK-LC-1, CD8, human leukocyte antigen (HLA) class I, and programmed cell death protein ligand-1 (PD-L1) were assessed via immunohistochemistry staining using the specimens obtained from the participants. The association between the expression of the abovementioned molecules and patient prognosis was investigated.
Results: KK-LC-1 expression was observed in 21 of 50 recruited cases (42%). However, no significant correlation was found between KK-LC-1 expression and patient prognosis. The prognosis was significantly better in lung cancer cases with KK-LC-1 expression in which CD8 T cells infiltrated the tumor. Regardless of the HLA class I expression or the PD-L1 expression, the KK-LC-1 expression in squamous cell lung cancer could not be detected as a significant prognostic factor. Furthermore, considering the polarity of the cancer tissue as epithelium, staining of KK-LC-1 tended to be strong in the area corresponding to the basal side of the tumor tissue. The Ki-67 expression was frequently observed in cancer cells on the basal side, which was consistent with the KK-LC-1 expression in representative four cases with KK-LC-1-positive squamous cell lung cancer.
Conclusions: Our results indicated that lung squamous cell cancer patients with KK-LC-1 expression and the tumor infiltrating CD8 T cells might exhibit better prognosis. KK-LC-1 might be highly expressed in cancer cells with high proliferative capacity. Larger cohort analysis is still required for further elucidation and validation of the results of this study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798488 | PMC |
| http://dx.doi.org/10.21037/tcr-21-1581 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer.
BMC Cancer
July 2024
Comprehensive Cancer Centre, Department of Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Purpose: There is mounting evidence that patients with liver cancer can benefit from Immune checkpoint inhibitors. However, due to the high cost and low efficacy, we aimed to explore new biomarkers for predicting the efficacy of immunotherapy.
Methods: Specimens and medical records of liver cancer patients treated at Drum Tower Hospital of Nanjing University were collected, and the expression of Kita-Kyushu lung cancer antigen-1 (KK-LC-1) in tissues as well as the corresponding antibodies in serum were examined to find biomarkers related to the prognosis of immunotherapy and to explore its mechanism in the development of liver cancer.
Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets.
J Cancer Res Clin Oncol
November 2023
Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Objective: Immunotherapy is an attractive treatment for breast cancer. Cancer-testis antigens (CTAs) are potential targets for immunotherapy for their restricted expression. Here, we investigate the expression of CTAs in breast cancer and their value for prognosis.
View Article and Find Full Text PDFSingle-cell sequencing on CD8 TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer.
J Immunother Cancer
August 2023
Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan
Article Synopsis
- CD8 tumor infiltrating lymphocytes (TILs) are present in non-small cell lung cancer (NSCLC), but their specific characteristics and responses to tumor antigens are not well understood.
- This study utilized advanced techniques like single-cell RNA and T-cell receptor sequencing to analyze CD8 TILs from lung cancer specimens, identifying various T-cell populations and their responses to specific tumor antigens.
- The findings revealed a cluster of exhausted T-cells with specific TCR clonotypes recognizing tumor antigens, highlighting differences in their differentiation and response to stimulation, which could help identify targets for immunotherapy in cancer treatment.*
KK-LC-1 as a therapeutic target to eliminate ALDH stem cells in triple negative breast cancer.
Nat Commun
May 2023
Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.
Failure to achieve complete elimination of triple negative breast cancer (TNBC) stem cells after adjuvant therapy is associated with poor outcomes. Aldehyde dehydrogenase 1 (ALDH1) is a marker of breast cancer stem cells (BCSCs), and its enzymatic activity regulates tumor stemness. Identifying upstream targets to control ALDH cells may facilitate TNBC tumor suppression.
View Article and Find Full Text PDFTargeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer.
J Transl Med
March 2023
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
Article Synopsis
- KK-LC-1, a cancer/testis antigen, is found to be highly expressed in triple-negative breast cancer tissues and is linked to poor patient survival outcomes.
- Silencing KK-LC-1 in cancer cells reduces their ability to grow, invade, and migrate, while increasing apoptosis and affecting the cell cycle, as demonstrated in both lab experiments and animal studies.
- The study identifies the small-molecule compound Z839878730, which selectively targets KK-LC-1 and shows potential anti-cancer effects on triple-negative breast cancer without harming normal breast cells, acting through specific signaling pathways.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!